
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid is well-positioned for future success with their proprietary drug delivery technology, PLEX, and strong partnerships and advancements for their product candidates. Despite challenges such as clinical and financing risks, a positive outcome of FDA interactions and potential approval of D-PLEX100 in 4Q26 could significantly increase PolyPid's value and support a $9 per share price target.
Bears say
PolyPid is a clinical-stage biopharmaceutical company that has potential in its D-PLEX technology platform and new Kynatrix technology, but it remains uncertain whether the company can successfully navigate the FDA's pre-approval inspection, which could be a key bottleneck. Despite reporting better-than-expected financials for the third quarter of 2025, the company still has a net loss and may need to raise additional funds to support its operations beyond 2026. The upcoming pre-NDA meeting in December 2025 may provide clarity on the potential commercial manufacturing and labeling for D-PLEX100, but questions remain around its indications and potential site inspections during initial batches.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares